NTR1011 not checked

Neutrolis

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“NTR-1011 will be presented as a solution for intravenous (IV) administration.”In the company’s words, NCT07237659 on ClinicalTrials.gov
Tested for
SLE (Systemic Lupus), RA - Rheumatoid Arthritis
Main trialPhase 1
“The goal of this clinical trial is to inform the safety and tolerability of NTR-1011 in treating adult patients diagnosed with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). It will also learn about the safety of NTR-1011 in healthy adult volunteers. The main questions it aims to answer are: * What is the highest dose of NTR-1011 that is safe and well tolerated, when given under the skin or into a vein? * How does the body process NTR-1011, and how does NTR-1011 affect the body? * Does the body develop an immune response to NTR-1011? * Are there early signs that NTR-1011…”In the company’s words, NCT07237659 on ClinicalTrials.gov

Other drugs for SLE (Systemic Lupus)

All 131 drugs for SLE (Systemic Lupus)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting 31 Mar 2027 Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow NTR1011

Following is part of Solo: you see every change to NTR1011 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in